. 2018 Oct 16;21(6):1345–1354. doi: 10.1038/s41436-018-0337-5

Table 2.

Frequencies of predicted high-risk phenotypes within the studied cohort (GS, GSA, and OMNI data combined) and gene-related drug consumption statistics in European Nordic countries

Gene	Phenotype	% of individuals (phenotype, source)			% of individuals (gene total)	Number of drug active substances affected	DDD^a/1000 inhabitants, (min–max)^b
		GS	GSA	OMNI
CYP2C19	Intermediate metabolizer	23.6	23.2	24.0	63.7	10	17.62–66.83
	Poor metabolizer	2.44	2.16	2.34
	Rapid metabolizer	31.2	30.7	31.2
	Ultrarapid metabolizer	6.86	7.40	7.23
CYP2C9	Intermediate metabolizer	25.8	26.1	25.1	28.4	2	7.08–16.26
CYP2C9	Poor metabolizer	2.40	2.49	2.32	28.4	2	7.08–16.26
CYP2D6	Intermediate metabolizer	3.93	3.26	2.96	7.65	16	9.16–15.92
	Poor metabolizer	4.96	4.07	3.67
	Ultrarapid metabolizer	2.36	0.27	0
CYP3A5	Intermediate metabolizer	13.5	12.8	11.9	13.2	1	0–0.5
CYP3A5	Normal metabolizer	0.62	0.51	0.55	13.2	1	0–0.5
CYP4F2	Higher dose phenotype	0.29	0.36	0.33	70.5	1	7.02–16.04
	Increased CYP4F2 activity	0.04	0.02	0.03
	Lower dose phenotype	71.3	69.8	71.3
DPYD	Intermediate metabolizer	1.36	0.90	0.87	0.92	3	0
DPYD	Poor metabolizer	0	0.006	0	0.92	3	0
IFNL3	Unfavorable response	58.5	56.7	56.7	56.8	3	0–0.23
SLCO1B1	Decreased function	34.0	34.9	35.2	40.1	1	6.13–62.9
SLCO1B1	Poor function	4.38	5.24	5.47	40.1	1	6.13–62.9
TPMT	Intermediate metabolizer	5.54	6.37	6.33	6.40	3	0.32–1.41
TPMT	Poor metabolizer	0.21	0.07	0.08	6.40	3	0.32–1.41
UGT1A1	Intermediate metabolizer	45.9	46.2	45.3	59.0	2	0–0.09
UGT1A1	Poor metabolizer	12.3	13.1	12.6	59.0	2	0–0.09
VKORC1	Decreased dose phenotype	56.5	57.5	57.5	57.4	1	7.02–16.04

GS genome sequencing, GSA Global Sequencing Array, OMNI HumanOmniExpress.

^aDrug daily dosage.

^bMin–max among Estonia, Finland, Sweden, Denmark, Norway.